Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name ABT-165
Trade Name
Synonyms Dilpacimab|ABT 165|ABT165
Drug Descriptions

Dilpacimab (ABT-165) is a bispecific antibody that binds to and inhibits signaling of both DLL4 and VEGF, which potentially results in tumor growth inhibition (PMID: 29592882).

DrugClasses DLL4 Antibody 7 VEGF Antibody 11
CAS Registry Number 1791420-09-1
NCIT ID C116750


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
ABT-165 ABT-165 0 1
ABT-165 + Budigalimab ABT-165 Budigalimab 0 1
ABT-165 + Budigalimab + Paclitaxel ABT-165 Budigalimab Paclitaxel 0 1
ABT-165 + Fluorouracil + Irinotecan + Leucovorin ABT-165 Fluorouracil Irinotecan Leucovorin 0 2
ABT-165 + Paclitaxel ABT-165 Paclitaxel 0 1

Additional content available in CKB BOOST